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Abstract. Multiple myeloma (MM) is an incurable disease of
malignant plasma cells. Recent therapeutic advancements
have resulted in improved response rates, however, there is
no improvement in overall survival, therefore, new therapeutics
are needed. Since the transferrin receptor is upregulated on
the surface of MM cells, we previously developed an antibody
fusion protein consisting of an IgG3 specific for the human
transferrin receptor 1 (TfR1, CD71) genetically fused to avidin
at its carboxy-terminus (ch128.1Av). We have previously
shown that ch128.1Av exhibits intrinsic cytotoxicity against
certain malignant B-cells by disrupting the cycling of the TfR
and decreasing TfR cell surface expression resulting in lethal
iron starvation. In addition, ch128.1Av can sensitize malignant
cells to apoptosis induced by gambogic acid, a herbal drug
used in Chinese medicine. In this study, we hypothesized that
ch128.1Av may also sensitize drug-resistant malignant B-cells
to chemotherapeutic agents by inhibiting key survival path-
ways. In this study we show that ch128.1Av sensitizes
malignant B-cells to apoptosis induced by cisplatin (CDDP).
The sensitization by ch128.1Av resulted in the inhibition of
the constitutively activated Akt and NF-κB survival/antiapop-
totic pathways and downstream decreased expression of anti-
apoptotic gene products such as BclxL and survivin. The direct
role of the inhibition of the Akt and NF-κB pathways by
ch128.1Av in CDDP-mediated cytotoxicity was demonstrated
by the use of specific chemical inhibitors and siRNA which
mimicked the effects of ch128.1Av. Overall, this study
provides evidence of the therapeutic potential of ch128.1Av as
a chemo-sensitizing agent in drug-resistant tumor cells.
Introduction
Increasing knowledge of the biology of multiple myeloma
(MM) is already contributing to the design of new drugs that
target cellular proteins or pathways involved in the patho-
physiology of this disease. These agents include inhibitors of
tyrosine-kinase receptors (TKR) (1), agents acting through
cell-surface receptors such as monoclonal antibodies against
plasma-cell antigens (2), and inhibitors of signaling pathways
such as NF-κB inhibitors (3-5) and Akt inhibitors (6,7). Patients
with MM are treated with chemotherapy and recently with
the proteasome inhibitor Bortezomib (8). However, there are
patients who either do not respond to such treatments or
develop resistance. Therefore, novel therapeutic approaches
are needed as alternative strategies to treat this disease.
Transferrin primarily functions as an iron transporter
through the blood. The transferrin receptor 1 (TfR1, CD71) is
ubiquitously expressed on normal cells at various levels (9).
TfR1 expression is increased in cells with a high proliferation
rate or on cells that require large amounts of iron. In normal
tissues, the constitutive expression of the TfR1 is limited to
the liver, epidermis, intestinal epithelium, vascular endothelium
of brain capillaries, and certain populations of blood cells
in the bone marrow (9). In contrast, high levels of TfR1
expression have been identified in many tumors including
MM (9). Due to its pivotal role in iron uptake, TfR1 is
expressed more abundantly in malignant cells compared to
normal cells and in many cases, this increased expression
correlates with tumor stage and poor prognosis (9,10). Due to
its extracellular accessibility and its upregulation on the
surface of malignant cells, the TfR1 has been widely used for
the delivery of many therapeutics into cancer cells by receptor-
mediated endocytosis (11).
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In order to target the TfR1, we previously generated a
mouse/human chimeric antibody fusion protein specific for
TfR1 (12-14). This fusion protein (ch128.1Av) contains the
variable regions of the murine antibody 128.1 and human
IgG3 constant regions that are genetically fused to avidin at
the carboxy-terminus of the heavy chains. This molecule was
originally designed as a delivery vehicle with the ability to
deliver many biotinylated anti-tumor compounds into cancer
cells. We have previously shown that ch128.1 delivers active
biotinylated molecules into cancer cells, including saporin, a
toxin derived from the plant Saponaria officinalis (12,15). We
have also shown that ch128.1Av exhibits intrinsic cytotoxic
activity alone against certain malignant B-cells (13,16). This
cytotoxicity is due to a disruption of the constitutive TfR1
cycling pathway that leads to decreased TfR1 surface expres-
sion and ultimately, after at least 48 h, lethal through iron
deprivation (13). More recently, we have demonstrated that
ch128.1Av enhances the cytotoxicity of gambogic acid, a
traditional Chinese medicine that can also bind the TfR1 (16).
The antibody fusion protein can also sensitize malignant
B-cells to gambogic acid-induced apoptosis (16).
In the current study, we hypothesized that ch128.1Av
may also sensitize malignant B-cells to more traditional
chemotherapeutic drugs. This hypothesis was tested and
the following were investigated: a) Does the combination
treatment of ch128.1Av and the chemotherapeutic drug cis-
diamminedichloroplatinum (II) (CDDP, also known as
cisplatin) result in enhanced cytotoxic effects? b) Does
ch128.1Av-mediated sensitization result from inhibition of
constitutively activated cell survival/anti-apoptotic pathways
such as the NF-κB and Akt pathways? c) Does inhibition of
NF-κB activity by ch128.1Av mediate, in part, CDDP-induced
sensitization to apoptosis? Does the NF-κB inhibitor, DHMEQ,
mimic ch128.1Av sensitization to CDDP? d) Is ch128.1Av-
induced inhibition of Akt activity responsible, in part, for the
sensitization of cancer cells to CDDP-induced apoptosis? Does
the Akt chemical inhibitor LY294002 or Akt siRNA mimic
ch128.1Av sensitization to CDDP? and e) Does the treatment
of malignant B-cells with ch128.1Av involve mitochondrial
signaling for apoptosis? The findings presented herein support
the above hypothesis.
Materials and methods
Reagents. RPMI-1640, opti-MEM and fetal bovine serum
(FBS) were purchased from Invitrogen (Carlsbard, CA, USA).
LY294002 was purchased from Merck Japan (Tokyo, Japan).
DHMEQ was a kind gift from Dr K. Umezawa (Keio Univer-
sity, Japan). Anti-BclxL, anti-cIAP1, anti-PARP, anti-caspase 9,
anti-survivin, anti-human phospho-Akt (Ser473), anti-Akt
and anti-ß-actin antibodies were obtained from Cell Signaling
Technology (Beverly, MA, USA). Secondary HRP-conjugated
anti-rabbit or anti-mouse IgG antibodies, Akt siRNA and
control scramble siRNA were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Protein A-agarose was purchased from
Pierce (Rockford, IL, USA). The Annexin V-FITC kit was
purchased from Beckman Coulter (Marseille, France).
Antibody-avidin fusion protein. ch128.1Av has been described
previously (12). Briefly, this molecule was expressed in the
murine myeloma cell line Sp2/0-Ag14 and purified from
culture supernatants by using affinity chromatography as
described (12,17). Purity was assessed by Simply blue (Invi-
trogen) staining of SDS-PAGE gels. All protein concentrations
were determined by the bicinchoninic acid based protein
assay (BCA Protein Assay, Thermo Fisher Scientific, Rockford,
IL, USA) and ELISA as described (17).
Cell lines. The human cell lines IM-9 (EBV-transformed
B-lymphoblastoid cell line originally isolated from the blood
of a patient with multiple myeloma) and RPMI-8226 (a
multiple myeloma cell line also isolated from the blood of a
patient with multiple myeloma) were obtained from Human
Science Technology (Osaka, Japan). Cells were cultured at
37°C, 5% CO2 in RPMI-1640 medium supplemented with
10% FBS, 1% NaHCO3 and 1% penicillin, streptomycin (v/v).
Determination of apoptosis by flow cytometry. Apoptosis was
detected by Annexin V/Propidium Iodide staining followed
by flow cytometry analysis as described previously (18).
Measurement of mitochondrial membrane depolarization.
The mitochondria-specific dye 3,3-dihexyloxacarbocyanine
(DiOC6; Invitrogen) was used to measure the mitochondrial
membrane potential in both cell lines before and after 24 h of
treatment with ch128.1Av as previously reported (19).
Western blotting. IM-9 and 8226 cells (4x105 cells/ml) were
seeded in a 100-mm dish containing 9 ml of the complete
medium. The cells were treated with indicated concentrations
of ch128.1Av for 24 h, washed 2 times with PBS, and then
treated with 10 μg/ml of CDDP for an additional 24 h. The
cells were harvested in PBS on ice and centrifuged at
3,500 rpm for 5 min. The cells were lysed in 100 μl of lysis
buffer (1% Triton X-100, 20 mM Tris, 137 mM NaCl, 1 mM
PMSF, 2 mM Na3VO4, and 10 μg/ml leupeptin). The cell
lysate was centrifuged at 15,000 x g for 10 min, and the super-
natant was used for further analysis. Protein concentrations
were determined using the Coomassie Brilliant Blue Method.
The proteins were denatured at 95°C for 5 min in loading
buffer (60 mM Tris, 2.5% SDS, 10% glycerol, 5% 2-ME,
and 0.01% bromophenol blue). Aliquots containing 70 μg of
total protein from each sample were separated by SDS-PAGE
and transferred onto a PVDF membrane at 200 mA for 1 h.
After the transfer, the membrane was washed for 30 min at
room temperature in a TBS-Tween buffer (20 mM Tris-HCl,
pH 7.6, containing 137 mM NaCl and 0.1% Tween-20)
supplemented with 5% non-fat milk. The membrane was
washed three times with TBS-Tween and probed for 1 h with
the primary antibody diluted at 1/300 with 5% non-fat milk
in TBS-Tween. After the membrane had been washed 6 times
with TBS-Tween, the membrane was incubated with a secon-
dary HRP-conjugated anti-rabbit or anti-mouse IgG antibodies
diluted at 1/3000 with 5% non-fat milk TBS-Tween for 1 h at
room temperature. Finally, after the membrane had been
washed with TBS-Tween eight times the proteins were
visualized on X-ray film with an ECL Western blotting
detection kit (Perkin Elmer Life Sciences, Tokyo, Japan).
Transfection with siRNA. Cells were cultured in 3 ml of Opti-
MEM medium supplemented with FBS. Transfections with
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targeted siRNA (Sigma-Aldrich) or control scramble siRNA
(Sigma-Aldrich) were performed using the Xtreme GENE
reagent (Roche Diagnostics Corporation, Indianapolis, IN,
USA), according to the manufacturer's instructions. To deter-
mine Akt siRNA-induced sensitization to CDDP-induced
apoptosis following transfection, the cells were treated with
CDDP for an additional 24 h, then were processed for the
Annexin V/Propidium Iodide staining and analyzed by flow
cytometry as described above.
Analysis of DNA binding activity. DNA binding activity was
measured by using the TransAM™ Transcription Factor
Assays kit (Active Motif, Tokyo, Japan) according to the
manufacturer's instructions.
Statistical analysis. Assays were set up in triplicates and the
results are expressed as the mean ± SD. Statistical analysis
was performed using the Student's t-test.
Results
ch128.1Av-induced sensitization of malignant B-cell lines to
apoptosis by CDDP. The malignant B-cell lines IM-9 and
8226 were used as model systems to investigate the effect of
ch128.1Av on the response of cancer cells to chemotherapeutic
drugs such as CDDP. The IM-9 and 8226 cell lines were
treated with different concentrations of ch128.1Av for 24 h
and followed by treatment with CDDP (10 μg/ml) for an
additional 24 h. The cells were then examined for apoptosis.
While treatment with ch128.1Av alone or CDDP alone
resulted in no significant apoptosis, the combination treatment
resulted in significant potentiation of apoptosis (Fig. 1). By
comparison, the sensitization of the cell line 8226 was more
potent than the sensitization of the IM-9 cell line. These
findings demonstrate that ch128.1Av is able to modify the
apoptotic pathway(s) in the cell lines by reducing the thres-
hold of resistance so that CDDP treatment can trigger
apoptosis. We then examined the potential underlying
mechanism by which ch128.1Av signals the cells and results
in chemosensitization.
Inhibition of the constitutively activated NF-κB pathway in
malignant B-cells by ch128.1Av. The above findings of
ch128.1Av-mediated sensitization to CDDP apoptosis may
have resulted from the inhibition of anti-apoptotic gene
products that are regulated by the NF-κB pathway. To test
this hypothesis, the cancer cells were treated with various
concentrations of ch128.1Av for 24 h and cell lysates were
prepared for Western blot analysis. Treatment of IM-9 cells
with ch128.1Av resulted in a significant inhibition of the
activation of NF-κB as evidenced by the decrease in phospho-
p65 at concentrations ≥16 nM ch128.1Av and complete
inhibition of phosphorylation at 32 nM (Fig. 2A, left panel).
There was no effect on total p65 protein level, suggesting
that the effect of ch128.1Av occurs at the activation level
and not at the expression level. ß-actin was used as a loading
control. For 8226 cells, there was significant decrease in the
levels of phospho-p65 at ≥8 nM ch128.1Av and more inhi-
bition at 32 nM (Fig. 2A, right panel). Like IM-9, there was
no effect on total p65 protein levels.
The inhibition of the NF-κB pathway by ch128.1Av as
shown above by Western blot analysis was also corroborated
by using a DNA-binding assay for NF-κB. Clearly, a concen-
tration of 16 nM was sufficient to significantly inhibit NF-κB
DNA-binding activity in IM-9 and 8226 cells (Fig. 2B). The
NF-κB inhibitor DHMEQ was used as an internal positive
control. The role of NF-κB-induced sensitization to CDDP-
induced apoptosis was further confirmed by the use of the
NF-κB inhibitor DHMEQ. Treatment of IM-9 (Fig. 2C, left
panel) and 8226 (Fig. 2C, right panel) cells with different
concentrations of DHMEQ (10 and 20 μM) resulted in
significant potentiation of sensitization to CDDP-induced
apoptosis. Single agents alone had no effect. These findings
show that blocking NF-κB activity can lead to sensitization
to CDDP-induced apoptosis, suggesting that NF-κB-induced
inhibition by ch128.1Av is involved in the chemosensitization
of malignant B-cells to CDDP-induced apoptosis.
Inhibition of the constitutively activated Akt pathway in
malignant B-cells by ch128.1Av. In addition to inhibition of the
NF-κB pathway by ch128.1Av shown above, the constitutively
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Figure 1. ch128.1Av sensitizes tumor cells to CDDP-induced apotosis. IM-9
(A) and 8226 cells (B) were pre-treated with various concentrations of
ch128.1Av for 24 h followed by treatment with CDDP (10 μg/ml) for an addi-
tional 24 h. Apoptosis was determined using the PI/Annexin-V as described
in methods. The data represent the mean values ±SD from 3 independent
experiments. p-value: cells treated with a single agent (ch128.1Av or CDDP)
vs. combined treatment with CDDP (Student's t-test).
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activated Akt pathway is also involved in the regulation of
resistance to apoptosis as well as its crosstalk with the NF-κB
pathway (20). We, therefore, hypothesized that ch128.1Av-
induced inhibition of NF-κB may have resulted from inhibition
of the Akt pathway. Treatment of IM-9 and 8226 with various
concentrations of ch128.1Av resulted in significant decrease
of phospho-Akt (ser 473) levels with no effect on the total Akt
levels (Fig. 3A). In IM-9 (Fig. 3A, left panel), treatment with
≥8 nM ch128.1Av resulted in decreased phospho-Akt levels
and there was complete inhibition at 32 nM. The concen-
tration range of ch128.1Av in the inhibition of phospho-Akt
was in the same range as observed in the inhibition of NF-κB
seen in Fig. 2A. The effect of ch128.1Av on 8226 was less
pronounced and the inhibition was observed at 32 nM of
ch128.1Av (Fig. 3A, right panel). These results suggested
that the inhibition of the Akt pathway by ch128.1Av may
also be involved in the sensitization of malignant B-cell lines
to CDDP apoptosis. To test this hypothesis, we used a specific
inhibitor of the Akt pathway, namely, LY294002. Treat-
ment of the cancer cells with various concentrations of
LY294002 (10-50 μM) and followed by treatment with CDDP
(1 and 5 μg/ml) resulted in significant enhancement of
apoptosis. In IM-9 cells, treatment with 50 μM LY294002 in
combination with CDDP (5 μg/ml) resulted in significant
potentiation of apoptosis (Fig. 3B, left panel). Likewise, in
8226 cells, treatment with 50 μM of LY294002 resulted in
significant enhancement of apoptosis in combination with
CDDP (5 μg/ml) (Fig. 3B, right panel).
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Figure 2. Inhibition of NF-κB by ch128.1Av and the role of NF-κB in tumor cell sensitization to CDDP-induced apoptosis. (A) ch128.1Av inhibits NF-κB
activation as evidenced by the decreased level of phospho-p65 in IM-9 (left) and 8226 (right) cells. Cells were treated with 0-32 nM of ch128.1Av for 24 h
and cell lysates were prepared and examined by Western blot analysis for phospho-p65, p65 and ß-actin expression. Blots are representative of 3 independent
but reproducible experiments. (B) NF-κB DNA-binding activity in IM-9 (left) and 8226 cells (right). Cells were treated with 0-32 nM of ch128.1Av for 24 h
and cell lysates were prepared and examined for DNA-binding analysis using Trans AM DNA-binding analysis kit as described in Materials and methods.
The NF-κB inhibitor, DHMEQ, was used as an internal positive control. p-value: medium control compared to treatment with 16 nM of ch128.1Av (Student's
t-test). (C) IM-9 (left) and 8226 cells (right) were treated with various concentrations of (-)-DHMEQ (0-20 μg/ml) for 2 h and treated with CDDP (10 μg/ml)
for an additional 24 h. Apoptosis was determined using the PI/Annexin-V method. p-value: single (-)-DHMEQ or CDDP treatment vs. combined treatment
(Student's t-test).
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The direct role of Akt in the sensitization to CDDP-induced
apoptosis was confirmed by the use of Akt siRNA. IM-9 and
8226 cells were treated with Akt siRNA or control siRNA for
24 and 48 h. Shown in Fig. 4A (left panel) treatment of IM-9
cells with Akt siRNA resulted in significant inhibition of Akt
as determined by Western blotting. Likewise, treatment of
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Figure 3. Inhibition of Akt activity by ch128.1Av and the direct role of Akt inhibition via LY294002 in the sensitization to CDDP-induced apoptosis. (A) The
ch128.1Av inhibits phospho-Akt in IM-9 cells (left) and 8226 cells (right). Cells were treated with 0-32 nM of ch128.1Av for 24 h and cell lysates were
prepared and examined by Western blot analysis for phospho-Akt, Akt and ß-actin. Blots are representative of 3 independent but reproducible experiments.
(B) Treatment of IM-9 cells (left) and 8226 cells (right) with a specific Akt inhibitor LY294002 results in sensitization to CDDP-induced apoptosis. IM-9 and
8226 cells were treated with various concentrations of CDDP (1 or 5 μg/ml) for 24 h in the presence or absence of LY294002 (0-50 μM) and apoptosis was
determined using the PI/Annexin-V method. *p-value: single cell treatment with LY294002 or CDDP vs. combinational treatment. (Student's t-test).
Figure 4. Direct inhibition of Akt by siRNA in cells results in sensitization to CDDP-induced apoptosis. (A) IM-9 (left) or 8226 (right) cells were treated with
8 nM of either Akt siRNA or control scramble siRNA for 0-48 h. Cell lysates were examined for total Akt levels by Western blot analysis. ·-tubulin served as
an internal control for loading. (B) Cells were treated with increasing concentrations of Akt siRNA for 48 h and CDDP (10 μg/ml) for an additional 24 h, and
apoptosis was determined using the PI/Annexin-V method. *p-value: single Akt siRNA or CDDP treatment vs. combined treatment (Student's t-test).
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8226 with Akt siRNA also resulted in inhibition of Akt as
shown in Fig. 4A, right panel. For sensitization to CDDP,
IM-9 and 8226 cells were treated with Akt siRNA or control
in the presence or absence of CDDP (10 μg/ml) and then
examined for apoptosis. As seen in Fig. 4B treatment of IM-9
and 8226 with the combination of Akt siRNA and CDDP
resulted in significant potentiation of apoptosis. These findings
corroborate the findings observed above with the Akt inhibitor
LY294002 that show that inhibition of the AKT pathway
plays a role in CDDP-mediated cytotoxicity. These findings
show that blockage of the Akt pathway can lead to chemo-
sensitization and suggest that ch128.1Av-mediated inhibition
of the Akt pathway, in addition to the NF-κB pathway, is also
involved in the sensitization of malignant B-cells to CDDP-
induced apoptosis.
Potential underlying mechanism of ch128.1Av-mediated
sensitization of malignant B-cells to apoptosis by CDDP. We
have previously shown that a high concentration of ch128.1Av
(50 nM) for treatment times of 48 h induces mitochondrial
depolarization (13). Thus, we determined if the concentrations
of ch128.1Av used in this study could also induce mito-
chondrial depolarization, which might play a role in its ability
to sensitize cells to CDDP-mediated apoptosis. Cells were
treated with various concentrations of ch128.1Av and examined
for the mitochondrial membrane potential. Treatment with
ch128.1Av resulted in significant mitochondrial membrane
depolarization starting at concentrations of 0.02 nM in both
IM-9 (Fig. 5A) and 8226 (Fig. 5B) cells. These findings suggest
that the membrane depolarization by ch128.1Av may result
in the downstream activation of the apoptosome and in combi-
nation with CDDP results in the potentiation of apoptosis.
In order to examine the effects mediated by ch128.1Av
downstream of the mitochondrion and the NF-κB and Akt
pathways, whole-cell lysates from cells treated with various
concentrations of ch128.1Av alone or in combination with
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Figure 5. ch128.1Av-induces mitochondorial membrane potential depolari-
zation in malignant B-cells. Mitochondorial membrane depolarization was
assessed in IM-9 cells (A) and 8226 cells (B) using the DiOC6 dye by flow
cytometry as described in Materials and methods. The cells were treated
with various concentrations of ch128.1Av (0.02-2.5 nM) for 24 h and then
examined for membrane potential. Values are expressed as Mean Fluores-
cence Intensity (MFI) of DiOC6 incorporation. Untreated cells are represented
as 100 and treated cells are calculated as percentage of untreated cells. The
data represent the mean ± SD of 3 independent experiments. p-value: medium
control vs. treatment with 16 nM of ch128.1Av (Student's t-test).
Figure 6. ch128.1Av sensitizes malignant B-cells to apoptosis by CDDP via
activation of the intrinsic apoptotic pathway. Total cell lysates derived from
IM-9 cells (A) and 8226 cells (B) treated with various concentrations of
ch128.1Av (0-32 nM) and CDDP (10 mg/ml) for 24 h were examined for
levels of expression for BclxL, cIAP-1, survivin, caspase-9 and PARP by
Western analysis. ß-actin served as an internal control for loading. The blots
are representative of three independent experiments.
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CDDP were examined by immunoblotting for the expression
levels of various proteins involved in these pathways. Treat-
ment of IM-9 cells with ch128.1Av for 24 h resulted in the
decrease of the anti-apoptotic gene products Bcl-xL, cIAP1
and survivin in the range of concentrations of 8-32 nM of
ch128.1Av (Fig. 6A). There was also cleavage of caspase-9
but only at 32 nM of ch128.1Av and there was no cleavage
of PARP with ch128.1Av alone. The cleavage of caspase-9
observed here is consistent with previous findings showing
caspase-9 activity at concentrations above 10 nM in IM-9
cells treated for more than 48 h (15). In IM-9 cells, the combi-
nation treatment of ch128.1Av with CDDP (10 μg/ml) resulted
in significant decrease in the expression levels of Bcl-xL,
cIAP1, and survivin (Fig. 6A). The combination treatment
also showed caspase-9 and PARP cleavage (Fig. 6A). In
8226 cells, treatment with ch128.1v alone also decreased the
expression levels of Bcl-xL, cIAP1 and PARP, but not
survivin (Fig. 6B). The combination treatment totally inhi-
bited the expression of all of these gene products (Fig. 6B).
Cleavage of caspase-9 and PARP were also increased by the
combination treatment, consistent with apoptotic cell death.
The downregulation of BclxL and survivin by ch1281-induced
inhibition of the Akt pathway was corroborated by treatment
with siRNA Akt (Fig. 4A). These findings support our
contention that the sensitizing ability of ch128.1Av is mediated,
in part, by the inhibition of anti-apoptotic gene products
regulated by the NF-κB and Akt pathways.
Discussion
This study provides evidence, for the first time, that treatment
of malignant B-cells with ch128.1Av inhibits the constitutive
NF-κB and Akt signaling pathways. This inhibition leads
downstream to downregulation of anti-apoptotic gene
products such as Bcl-xL and survivin and sensitized the cells
to CDDP-induced apoptosis. The proposed model for the
sensitization activity of ch128.1Av is shown in Fig. 7. The
inhibition of NF-κB pathway was determined by decreased
levels of phosphorylated p65. The inhibition of NF-κB
activity and downregulation of anti-apoptotic gene products
by ch128.1Av and chemosensitization was corroborated by
the use of the NF-κB inhibitor DHMEQ, which mimicked
ch128.1Av in the inhibition of NF-κB and chemosensiti-
zation to CDDP. Treatment of IM-9 and 8226 cells with
ch128.1Av significantly inhibited the constitutive activity of
the PI3K/Akt signaling pathway. Inhibition of this pathway
resulted downstream in the inhibition of Bcl-xL and survivin
and sensitized the cells to CDDP-induced apoptosis. The role
of Akt pathway in ch128.1Av-induced sensitization of cancer
cells to CDDP-induced apoptosis was corroborated by the
use of both the PI-3K inhibitor LY294002 and by the use of
siRNA for Akt. Treatment of IM-9 and 8226 cells with
LY294002 or Akt siRNA inhibited the Akt pathway and both
Bcl-xL and survivin expression and sensitized the cells to
CDDP-induced apoptosis. The inhibition of Akt and NF-κB
activities by ch128.1Av with the combination treatment with
CDDP resulted in the activation of the mitochondrial apoptotic
pathway and in the activation of caspase-9, PARP cleavage
and apoptosis. These findings establish the potential therapeutic
implication of ch128.1Av alone or in combination with sub-
toxic doses of chemotherapeutic drugs in drug-resistant
malignant B-cells.
In mammals, the NF-κB contains five members: Rel-A
(p65), Rel-B, c-Rel, NF-κB (p50 and its precursor p100) and
NF-κB 2 (p52 and its precursor p100), the most abundant
being the p65/p50 heterodimer (21). In normal cells, NF-κB
activity is tightly controlled by IκB inhibitory proteins. NF-κB
activation can be induced by a variety of stimuli resulting in
the phosphorylation of IκB, ubiquitination and IκB degradation
by the 26S proteasome, allowing the translocation of NF-κB
to the nucleus and activation of gene transcription. NF-κB
phosphorylation is catalyzed by the multi-protein IKK
complex, which phosphorylates and activates of the upstream
NIK (21,22). Here, we show a significant decrease of the
phosphorylation state of p65 at less than 8 h following treat-
ment, suggesting of a novel function of ch128.1Av as a
negative regulator of the NF-κB pathway.
NF-κB/Rel transcription factors bind to NF-κB control
elements present in the promoter of a wide variety of target
genes that regulate cellular differentiation, proliferation,
survival and apoptosis (21,22). Activation of the NF-κB
pathway is, in part, responsible for the transcriptional activa-
tion and expression of anti-apoptotic Bcl-2 family members
which protect tumor cells from drug-induced apoptosis
(21-23). In this study, we show that inhibition of the NF-κB
pathway by ch128.1Av resulted in the down-regulation of
Bcl-xL and survivin. We have reported that inhibition of
Bcl-xL is critical for chemosensitization (23,24), and hence,
our findings suggest that inhibition of Bcl-xL and survivin
correlate with ch128.1Av-induced sensitization to CDDP.
Akt is involved in mediating various biological respon-
ses such as inhibition of apoptosis and stimulation of cell
INTERNATIONAL JOURNAL OF ONCOLOGY  36:  1299-1307,  2010 1305
Figure 7. Schematic diagram of the mechanism by which ch128.1Av
sensitizes malignant B-cells to apoptosis by chemotherapeutic drugs.
Malignant B-cells constitutively express NF-κB and Akt activating pathways.
These result downstream in the transcription and expression of various
gene products that regulate cell survival, proliferation and resistance to
apoptosis. The tumor cells overexpress the transferrin receptor. Upon
binding of ch128.1Av to its corresponding transferrin receptor, the complex
is internalized and several modifications take place in the cancer cells. Both
the NF-κB and Akt activating pathways are inhibited and consequently,
inhibition of cell survival, proliferation and anti-apoptotic gene products are
observed. In addition, ch128.1Av also affects the mitochondria and
depolarizes the membrane potential. Likewise, treatment with CDDP also
affects the mitochondria, however, the combination treatment results in
potentiation of apoptosis in the resistant malignant B-cells.
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proliferation (20). Phosphorylation of Akt at serine or threo-
nine residues activates the kinase activity of Akt. Activation
of Akt can be mediated by various events, namely, binding of
ligand to receptors on the cell membrane and causing autophos-
phorylation in the intracellular domain of the receptor. Thus,
PI3k is recruited to the phosphothyrosine residues and becomes
activated. In B-cells, PI3k is activated by BCR via SYK and
BCAP (B-cell receptor associated protein). PI3k then phospho-
rylates membrane-bound PIP2 to generate PIP3. The binding
of PIP3 to the PH domain anchors Akt to the plasma membrane
and allows its phosphorylation and activation of PDK1. Also,
Akt can be activated by cellular stress such as heat shock,
UV, deschemia, hypoxia and oxidated stress (20).
The PI3K-Akt signaling pathway regulates many normal
cellular processes and aberrant activation of the PI3K-Akt
pathway has been widely implicated in many cancers (20).
The PI3K-Akt pathway is a key regulator of cell survival
through multiple downstream targets. IM-9 and 8226 cells
exhibit constitutive activation of the Akt pathway. We have
previously demonstrated that anti-CD20 monoclonal anti-
body, rituximab, inhibited the Akt pathway, leading to
inhibition of Bcl-xL and ultimately to chemosensitization via
the mechanism described above (23). Treatment of malignant
B-cells with ch128.1Av resulted in decreased activation of
the Akt pathway as well as depolarization of the mitochondrial
membrane. However, little caspase-9 activation was observed
(as expected) with ch128.1Av treatment alone due to the
short treatment time of 24 h. Previous studies have shown
activation of caspase-9 and -3 in cells treated with ch128.1Av
for more than 48h (13,15). Our results demonstrate that
treatment of IM-9 and 8226 cells with ch128.1Av in combi-
nation with CDDP significantly suppressed expressions of
Bcl-xL, survivin and cIAP1. Taken together, the combined
treatment of ch128.1Av with CDDP resulted in enhanced
cytotoxicity that was stronger and occurred faster compared
to ch128.1Av alone treated cells. In addition, the combination
treatment resulted in the activation of the mitochondrial apop-
totic pathway.
Various mechanisms contribute to the Akt pathway in
tumors including perturbation of upstream tensen, homolog
deleted in chromosome 10 (PTEN) and phosphatidylinositol
triphosphate (PIP3). Others include autocrine or paracrine
stimulation of receptor tyrosine kinases and overexpression
of growth factor receptors and/or RAS activation. Targeting
of Akt directly or indirectly inhibits cell proliferation, promotes
apoptosis and/or reverses sensitivity to chemotherapy (20).
Cross-talk between the PI3K and the NF-κB pathway has been
reported in a number of systems (25). Thus, the observed
findings of ch128.1Av inhibition of NF-κB and Akt may have
resulted from this cross-talk. Although we can not rule out
the involvement of other pathways, in the present study we
show that both the NF-κB and Akt pathways play an important
role in ch128.1Av-mediated chemosensitization of malignant
B-cells to CDDP-induced cytotoxicity.
In conclusion, our findings here demonstrate, for the first
time, that ch128.1Av is able to potentiate CDDP-induced
apoptosis in IM-9 and 8226 cancer cells via inhibition of
the constitutively activated Akt and NF-κB pathways and
expression of downstream anti-apoptotic molecules. Thus,
ch128.1Av-induced cytotoxicity is not only due to the iron
deficiency, but also to the inhibition of anti-apoptotic molecules
such as cIAPs, Bcl-xL and survivin. In addition, ch128.1Av
induces mitochondrial membrane depolarization and the
combination of ch128.1Av and CDDP through the activation
of the intrinsic apoptotic pathway results in enhanced apoptosis.
Our data suggest that ch128.1Av can effectively break the
tumor cell resistance to CDDP at very low concentrations and
could thereby support the clinical applicability of a combi-
nation of ch128.1Av and CDDP in the treatment of B-cell
malignancies.
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